Table 2 Primary and secondary outcomes
Group (n = 28 per group) | Risk difference, mean (95% CI) | P* | ||
|---|---|---|---|---|
Parameter | Landiolol, n (%) | Placebo, n (%) | ||
Primary outcome | ||||
AF96h in FAS | 6 (21.4) | 5 (17.9) | 3.6 (− 17.2 to 24.4) | 1.00 |
AF96h in PPS | 5 (19.2) | 4 (15.4) | 3.9 (− 16.7 to 24.4) | 1.00 |
Secondary outcomes | ||||
Count data | ||||
AF24h | 3 (10.7) | 2 (7.1) | 3.6 (− 11.3 to 18.4) | 1.00 |
Clavien grade ≥ II | 11 (39.3) | 14 (50.0) | − 10.7 (− 36.6 to 15.7) | 0.59 |
Clavien grade ≥ III | 7 (25.0) | 7 (25.0) | 0.0 (− 22.7 to 22.7) | 1.00 |
Continuous data, days | Mean ± SE | Mean ± SE | Mean difference (95% CI) | t test |
Median (IQR) | Median (IQR) | |||
ICU stay | 4.8 ± 0.38 | 4.6 ± 0.32 | 0.14 | 0.78 |
3.5 (3–6) | 4.0 (3–6) | (− 0.9 to 1.1) | ||
Hospital stay | 30.8 ± 5.1 | 28.1 ± 3.0 | 2.6 | 0.66 |
22 (17–34) | 21 (18–34) | (− 9.2 to 14.5) | ||